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Abstract
The host protein TRIM5a inhibits retroviral infection at an early post-penetration stage by targeting the incoming viral
capsid. While the detailed mechanism of restriction remains unclear, recent studies have implicated the activity of cellular
proteasomes in the restriction of retroviral reverse transcription imposed by TRIM5a. Here, we show that TRIM5a is rapidly
degraded upon encounter of a restriction-susceptible retroviral core. Inoculation of TRIM5a-expressing human 293T cells
with a saturating level of HIV-1 particles resulted in accelerated degradation of the HIV-1-restrictive rhesus macaque TRIM5a
protein but not the nonrestrictive human TRIM5a protein. Exposure of cells to HIV-1 also destabilized the owl monkey
restriction factor TRIMCyp; this was prevented by addition of the inhibitor cyclosporin A and was not observed with an HIV-
1 virus containing a mutation in the capsid protein that relieves restriction by TRIMCyp IVHIV. Likewise, human TRIM5a was
rapidly degraded upon encounter of the restriction-sensitive N-tropic murine leukemia virus (N-MLV) but not the
unrestricted B-MLV. Pretreatment of cells with proteasome inhibitors prevented the HIV-1-induced loss of both rhesus
macaque TRIM5a and TRIMCyp proteins. We also detected degradation of endogenous TRIM5a in rhesus macaque cells
following HIV-1 infection. We conclude that engagement of a restriction-sensitive retrovirus core results in TRIM5a
degradation by a proteasome-dependent mechanism.
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Introduction
Retroviruses exhibit a restricted host range due to the
requirement for specific interactions between viral and host
proteins to complete the viral life cycle. Also limiting retroviral
tropism are several recently identified intracellular antiviral factors
([1–5]); reviewed in [6–10]). The prototypical restriction activity,
Fv1, was first detected in the 1970s as differential susceptibility of
inbred mice strains to the Friend leukemia virus [11–13]. Fv1
blocks infection of murine leukemia viruses (MLV) at a stage
following fusion but prior to integration [14,15]. The block to
infection can be overcome at high multiplicities of infection (m.o.i.)
or by pretreatment of target cells with non-infectious virus like
particles (VLPs) [11,16]. Susceptibility to Fv1 restriction is
determined by the sequence of the viral capsid protein (CA)
[17–19]. The gene encoding Fv1 was identified in 1996 by
positional cloning [1]; yet the molecular mechanism by which Fv1
inhibits MLV infection remains poorly defined.
Recent investigations have identified additional restriction
activities present in human and simian cells that govern the
tropism of lentiviruses, including human and simian immunode-
ficiency viruses (HIV and SIV) [20–25]. Like Fv1, these
restrictions target the incoming viral capsid [23,25–27]. One
factor, TRIM5a, is responsible for post-entry restriction of HIV-1
in many simian cell lines [3,28–31]. Expression of the rhesus
macaque TRIM5a protein (TRIM5arh) in human cells renders
them highly restrictive to infection by HIV-1 [3]. Unlike Fv1,
TRIM5a acts at a stage prior to completion of reverse
transcription [3,20,23,24]. The human genome encodes a
TRIM5a protein (TRIM5ahu) that restricts multiple retroviruses
including N-tropic MLV (N-MLV), feline immunodeficiency virus
(FIV), and equine infectious anemia virus (EIAV) but does not
efficiently restrict HIV-1 [29,30,32–37]. TRIM5a cDNAs have
now been cloned from multiple primate species; these differentially
restrict infection by HIV-1, HIV-2, and SIV [28,31].
Shortly after the identification of TRIM5a, a second HIV-1
restriction factor was identified in owl monkeys [4,5]. This protein,
TRIMCyp, is the apparent result of a LINE1-mediated retro-
transposition event in which the cyclophilin A (CypA) mRNA was
inserted into the TRIM5 locus resulting in a functional fusion
protein [4]. TRIMCyp potently inhibits HIV-1 infection by
interacting with an exposed loop on the surface of the CA via the
CypA domain. The discovery of TRIMCyp provided a simple
explanation for the ability of cyclosporin A (CsA), which inhibits
CypA binding to CA, to render owl monkey cells permissive to
HIV-1 infection [38]. Mutations in the CypA binding loop that
result in a failure to bind CypA also result in a loss of restriction by
TRIMCyp [4,5]. More recently, novel TRIM5-CypA proteins
have also been identified in other primate species [39–42].
TRIM5a and TRIMCyp are members of the tripartite motif
family of proteins, which encode RING, B-Box, and coiled-coil
(RBCC) domains [43]. TRIM5a is the longest of the three
isoforms (a, c, and d) generated from the TRIM5 locus by
alternative splicing of the primary transcript. While all three
TRIM5 isoforms contain identical RBCC domains, the a-
transcript also encodes the B30.2/SPRY domain required for
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[29,30,33,34,36,44–46]. The coiled-coil domain promotes the
multimerization of TRIM5a molecules that is required for efficient
restriction [44,47,48]. While the precise function of the B-Box
domain is unclear, deletion of this region results in total loss of
restriction potential thus indicating its importance [44,49]. The
RING domain of TRIM5a is also required for full restriction
activity, as mutants that lack this domain or in which proper folding
is impaired are severely impaired for restriction and have altered
cellular localization [3,44,49]. Substitution of RING domains from
other human TRIM proteins results in changes in both the timing of
restriction (i.e. pre- vs. post-reverse transcription) and the intracel-
lular localization of the restriction factor [37,50–52].
RING domains are commonly associated with ubiquitin ligase
(E3) activity facilitating specific transfer of ubiquitin from various
ubiquitin-conjugating (E2) proteins to substrates (reviewed in
[53,54]). Polyubiquitylation of proteins commonly targets them for
intracellular degradation by proteasomes. TRIM5a can be
ubiquitylated in cells [55], but a role for this modification in
TRIM5a stability or restriction has not been established. The d
isoform of TRIM5, which encodes an identical RING domain to
TRIM5a, exhibits E3 activity in vitro and mutation of the RING
domain abolishes this activity [56]. The presence of a RING
domain on TRIM5a suggested that the restriction factor might
function by transferring ubiquitin to a core-associated viral
protein, thus targeting it for proteasomal degradation. However,
such a modification has not been detected, and the magnitude of
restriction imposed by TRIM5a was not altered in cells in which
the ubiquitination pathway was disrupted [57]. Nonetheless,
recent studies have shown that proteasome inhibitors relieve the
TRIM5a-dependent inhibition of reverse transcription, yet a block
to HIV-1 nuclear entry remains [58,59].
Based on these findings implicating the proteasome in
TRIM5a-dependent retroviral restriction, we hypothesized that
restriction by TRIM5a leads to proteasomal degradation of a
TRIM5a-viral protein complex. Here we show that inoculation of
TRIM5a-expressing cells with a restricted retrovirus results in
accelerated degradation of TRIM5a itself. Destabilization of
TRIM5a was tightly correlated with the ability of the restriction
factor to block infection by the incoming virus. Proteasome
inhibitors prevented HIV-1-induced degradation of TRIM5arh
when added to cells prior to virus inoculation. These data suggest a
functional link between proteasomal degradation of TRIM5a and
the ability of TRIM5a to restrict an incoming retrovirus.
Results
Exposure of Cells to HIV-1 Destabilizes TRIM5a
We hypothesized that TRIM5a itself might be degraded as a
consequence of the post-entry restriction process. To test this,
TRIM5arh-expressing 293T cells were cultured in the presence of
cycloheximide to arrest protein synthesis and then challenged with
VSV-G-pseudotyped HIV-1 particles. At various times post-
infection, cells were harvested for analysis of TRIM5a levels by
quantitative immunoblotting. In control cells not exposed to virus,
the TRIM5a level declined at a slow rate, eventually leveling off to
55% of the original level after 4 hours (Figure 1A). By contrast,
inoculation with HIV-1 induced a more rapid decrease in the
TRIM5a level resulting in 85% loss after 4 hours. Analysis of data
from 4 experiments indicated that the decay of TRIM5a was
significantly faster in the HIV-1-inoculated cultures relative to the
control (Figure 1B). The stability of TRIM5a in our cells differs in
terms of time as compared to previously published reports using
Hela cells [55]. In additional studies we observed a similar
destabilizing effect of HIV-1 exposure on TRIM5arh in HeLa cells
(data not shown).
Exposure of target cells to saturating levels of virus or VLPs can
overcome restriction by TRIM5a. To determine whether the
decay of TRIM5arh was related to saturation of restriction, we
inoculated TRIM5arh–expressing cells with various doses of a
GFP-encoding virus in the presence of cycloheximide for a fixed
period of time and harvested the cells to quantify TRIM5a levels.
To probe the relationship between saturation of restriction and
TRIM5a degradation, a portion of the harvested cells were
replated and cultured for 48 hours, and the extent of infection
determined by flow cytometric analysis of GFP expression. The
results showed that the ability to detect degradation of TRIM5arh
was strongly dependent on the dose of virus used (Figure 1C).
Furthermore, the TRIM5a level following inoculation was
inversely related to the overall extent of infection (Figure 1D).
These results indicate that HIV-1-induced degradation of
TRIM5a is correlated with saturation of restriction, likely due to
a requirement to engage most of the restriction factor to detect the
loss of the protein.
Human TRIM5a Stability is Not Affected by HIV-1
Human TRIM5a does not efficiently restrict HIV-1 infection.
To further probe the link between restriction and TRIM5a
destabilization, we analyzed the stability of the human TRIM5a
protein following challenge of cells with HIV-1. As previously
shown in Figure 1, HIV-1 challenge of TRIM5arh-expressing
293T cells resulted in a more rapid loss of the protein vs. mock-
infected cells (Figure 2A and B). TRIM5ahu was intrinsically less
stable than TRIM5arh, as indicated by its more rapid decay in the
mock-infected cultures (Figure 2B and C). However, inoculation
with HIV-1 did not result in further destabilization of TRIM5ahu,
indicating that the HIV-1-induced degradation of TRIM5arh is
not a nonspecific cellular response to the viral challenge. These
results suggest that the loss of TRIM5arh depends on its ability to
recognize the HIV-1 core.
Author Summary
Recent studies have identified several cellular proteins that
restrict infection by a variety of retroviruses. One of these
restriction factors, TRIM5a, is partially responsible for the
differences in susceptibility of monkeys and humans to SIV
and HIV-1, respectively. TRIM5a inhibits retrovirus infection
soon after penetration into the target cell by associating
with the viral protein CA, which forms the polymeric
capsid shell of the viral core. Although the detailed
mechanism of restriction is unknown, TRIM5a is postulated
to alter the stability of the viral core, resulting in a failure to
complete reverse transcription. The activity of cellular
proteasomes, which are responsible for intracellular
protein degradation, has also been implicated in TRIM5a-
dependent attenuation of retroviral reverse transcription.
In this study, we show that cellular TRIM5a is rapidly
degraded in cells exposed to a restriction-sensitive
retrovirus but not in cells infected with an unrestricted
virus. Virus-induced degradation of TRIM5a was depen-
dent on cellular proteasome activity, as inhibition with
drugs blocking proteasome function also inhibited degra-
dation of TRIM5a. These results provide additional support
for a role of proteasomal degradation in TRIM5a-depen-
dent retrovirus restriction and suggest a novel mechanism
by which binding of TRIM5a to the viral capsid prevents
infection.
TRIM5a Is Degraded upon Restriction of HIV-1
PLoS Pathogens | www.plospathogens.org 2 May 2008 | Volume 4 | Issue 5 | e1000074Exposure to Restriction-Sensitive HIV-1 Destabilizes
TRIMCyp
The owl monkey restriction factor TRIMCyp restricts HIV-1
by binding to an exposed loop on the surface of CA. Restriction
can be prevented by addition of CsA or amino acid substitutions in
CA that reduce CypA binding. We therefore asked whether
TRIMCyp would also be destabilized following encounter of HIV-
1. 293T cells expressing TRIMCyp were treated with cyclohex-
imide and then challenged with VSV-G pseudotyped HIV-1
particles. As a control, parallel cultures were inoculated in the
presence of a CsA concentration known to abolish TRIMCyp
restriction of HIV-1. In the control mock-inoculated cells,
TRIMCyp was stable in the cells during the six-hour time course
(Figure 3A). Challenge with HIV-1 resulted in accelerated loss of
TRIMCyp. In the cultures containing CsA, the HIV-1-induced
loss of TRIMCyp was markedly reduced (Figure 3B).
Figure 1. Destabilization of TRIM5a upon challenge of cells
with HIV-1. (A) Immunoblot analysis of TRIM5a in cells challenged
with HIV-1. 293T cells expressing HA-tagged TRIM5arh were pretreated
for 1 hour with cycloheximide at 37uC. Cells were then challenged with
stock solutions of HIV-1(VSV) or media alone (Mock). (B) Quantitation of
TRIM5a levels utilizing Odyssey Band imaging software. The TRIM5a
levels are expressed as a percentage of the ratio of TRIM5a:actin signal
to the zero hour sample TRIM5a:actin signal. Shown are the mean
values and standard deviations obtained in four independent
experiments. h.p.i.=Hours post infection. (C) Immunoblot analysis of
TRIM5a in cells challenged with HIV-1. 293T cells expressing HA-tagged
TRIM5arh were pretreated for 1 hour with cycloheximide at 37uC. Cells
were then challenged with media alone (Mock) or the indicated amount
of pseudotyped HIV-GFP expressed as quantity of p24 (CA) for a period
of three hours. (D) Relationship of TRIM5a level to permissivity of target
cells. A portion of the cultures harvested in (C) were recultured for
48 hours and subsequently analyzed for GFP expression by flow
cytometry. Shown are the mean values for the two replicates for both
TRIM5a levels and extent of infection.
doi:10.1371/journal.ppat.1000074.g001
Figure 2. Rhesus macaque, but not human TRIM5a, is less
stable in cells challenged with HIV-1. (A) 293T cells expressing HA-
tagged TRIM5arh or TRIM5ahu were pretreated for 1 hour with
cycloheximide then exposed to VSV-G pseudotyped HIV-1 or media
alone as in Figure 1. TRIM5a was detected by immunoblotting with HA-
specific antibody. Integrated intensity values for the individual bands
are shown in Figure S1. (B and C) Quantitation of TRIM5arh (B) and
TRIM5ahu levels utilizing Odyssey imaging software. Data shown are
from one representative of three independent experiments.
doi:10.1371/journal.ppat.1000074.g002
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TRIMCyp is correlated with the specificity of restriction. HIV-1
containing the G89V mutation in the CypA binding loop of CA is
incapable of binding CypA and is also not restricted by
TRIMCyp. However, this viral mutant is susceptible to TRIM5arh
restriction. Parallel cultures of 293T cells expressing either
TRIMCyp or TRIM5arh were treated with cycloheximide and
then challenged with equivalent quantities of VSV-G pseudotyped
HIV-GFP particles or the G89V CA mutant virus. As seen in
Figure 3C, exposure to wild type HIV-1 induced accelerated loss
of both TRIMCyp and TRIM5arh. By contrast, exposure to the
G89V mutant particles resulted in loss of TRIM5arh but not
TRIMCyp. These results indicate that exposure of cells to HIV-1
results in destabilization of TRIMCyp by a mechanism requiring
recognition of the incoming HIV-1 core by the restriction factor.
Human TRIM5a is Destabilized Upon Encounter of N-
tropic MLV
TRIM5ahu cannot restrict HIV-1 or B-tropic MLV but potently
restricts N-MLV. To further test the link between TRIM5a
destabilization and retrovirus restriction, we challenged 293T cells
stably expressing TRIM5ahu with N- and B-tropic MLV viruses
and measured TRIM5a levels following infection. The GFP-
transducing N- and B-tropic MLV stocks were first titrated on
nonrestrictive CrFK cells (Figure S2, detailed in Text S1) then
normalized to ensure equivalent dosing. Mock-treated cells lost
TRIM5ahu at a slow rate (t1/2,2.5 h; Figure 4A). Challenge with
B-MLV did not significantly affect the rate of TRIM5ahu decay
(Figure 4A). By contrast, cells challenged with an equivalent
quantity of N-MLV showed accelerated loss of TRIM5ahu (t1/2
,1 h) (Figure 4A and 4B). The relative band intensities of the
TRIM5a levels for this experiment were calculated and are
represented in the graph in Figure 4B. These results, together with
the TRIM5a and TRIMCyp data, establish a strong correlation
between virus-induced TRIM5a destabilization and the specificity
of restriction.
Figure 3. TRIMCyp is destabilized in cells challenged with HIV-
1. (A) 293T cells expressing the myc-His6 tagged TRIMCyp were
pretreated for 1 hour with cycloheximide. Cells were then challenged
with HIV-1(VSV) and either ethanol carrier (HIV-1) or CsA (HIV-1+CsA), or
with media alone (Mock). All stocks contained cycloheximide. (B)
Quantitation of TRIMCyp levels as described in the legend to Figure 1B.
Data in this figure are from one of two independent experiments. (C)
293T cells expressing either myc-His6 tagged TRIMCyp or HA-tagged
TRIM5arh were pretreated for 1 hour with cycloheximide. Cells were
then challenged for 5 hours with stock solutions of VSV-G pseudotyped
HIV-GFP (WT), VSV-G pseudotyped HIV-GFP with the G89V capsid
mutation (G89V), or medium alone (M). (D) Quantitation of TRIMCyp
and TRIM5a levels as described in legend to Figure 1B. Data in (D) are
expressed as the mean values of four determinations from two
experiments, with error bars representing one standard deviation.
doi:10.1371/journal.ppat.1000074.g003
Figure 4. Human TRIM5a is destabilized upon challenge of cells
with N-tropic but not B-tropic MLV. (A) 293T cells expressing HA-
tagged TRIM5ahu were pretreated for 1 hr with cycloheximide and
exposed to stocks of VSV-G-pseudotyped N- or B-tropic MLV or media
alone (Mock). Integrated intensity values for the individual bands are
shown in Figure S3. (B) Quantitation of TRIM5a levels utilizing Odyssey
Band imaging software. Data shown are from one representative of
three independent experiments.
doi:10.1371/journal.ppat.1000074.g004
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Lentiviral Restriction in Old and New World Monkeys
TRIM5a proteins from different primates differ in their ability to
restrict specific lentiviruses. For example, tamarin monkey TRIM5a
(TRIM5atam) restricts SIVmac but not HIV-1, while spider monkey
TRIM5a (TRIM5asp) restricts both viruses. To further test the
correlation between virus-induced loss of TRIM5a and antiviral
specificity, we stably expressed the TRIM5atam and TRIM5asp
proteins in 293T cells and challenged them with equivalent titers of
VSV-pseudotyped HIV-1 and SIVmac239 GFP reporter viruses (as
determined by titration on permissive CrFK cells). The cell lines
were found to restrict the respective viruses by at least ten-fold (data
not shown). Immunoblot analysis of post-nuclear lysates revealed
that TRIM5arh was specifically destabilized when challenged with
HIV-1 but not upon SIVmac challenge (Figure 5A). By contrast, the
SIV-restrictive TRIM5atam was destabilized only in response to
SIVmac challenge (Figure 5A). TRIM5asp, which restricts both
viruses, was degraded in response to challenge with either virus
(Figure 5A and B). These results further strengthen the correlation
between the specificity of retrovirus restriction and virus-induced
destabilization of TRIM5a.
HIV-1-Induced Destabilization of TRIM5a Requires
Proteasome Activity
A major mechanism for cellular protein degradation is via the 26S
proteasome. Previous studies have shown that the turnover of
TRIM5a isdependent oncellularproteasomeactivity.Furthermore,
inhibition of proteasome activity overcomes the early block to
reverse transcription imposed by TRIM5a.W ea s k e dw h e t h e rH I V -
1-induced destabilization of TRIM5arh is dependent on proteasome
activity. As previously reported [55], treatment of cells with the
proteasome inhibitor MG132 resulted in an accumulation of
TRIM5a protein (Figure 1, 0 H.p.i.). MG132 also prevented the
HIV-1-induced destabilization of TRIM5arh (Figure 6A and B).
Additional studies revealed that epoxomicin, a more specific
proteasome inhibitor, also blocked the HIV-1-induced degradation
of TRIM5arh (data not shown). By contrast, infection by HIV-1 in
thepresenceoftheS-cathepsininhibitorE64didnotpreventHIV-1-
induced TRIM5arh degradation (data not shown), suggesting that
endosomal proteases are not responsible for TRIM5arh destabiliza-
tion. We conclude that the virus-induced degradation of TRIM5a is
dependent on cellular proteasome activity.
To determine whether HIV-1-induced destabilization of
TRIMCyp depends on proteasome activity, we challenged
TRIMCyp-expressing 293T cells with either restricted HIV-GFP
or unrestricted HIV.G89V-GFP in the presence or absence of
MG132. As shown in Figure 6C, MG132 prevented the HIV-1-
induced loss of TRIMCyp. Infection with the unrestricted G89V
virus did not alter TRIMCyp stability, while addition of MG132
stabilized the restriction factor.
HIV-1-Induced Destabilization of Endogenous TRIM5a in
Primate Cells
All of the previous experiments studying TRIM5a stability were
conducted in transduced 293T cell lines in which TRIM5a was
detected by virtue of a hemagglutinin epitope tag. In this setting, it
Figure 5. Destabilization of primate TRIM5a proteins is correlated with restriction of HIV-1 and SIVmac239. (A) 293T cells expressing
HA-tagged TRIM5arh, TRIM5atam (tamarin monkey), TRIM5asp (spider monkey), and were pretreated for 1 hour with cycloheximide then exposed to
stocks of VSV-G pseudotyped HIV-GFP, SIV-GFP, or media alone (Mock). (B). Quantitation of relative TRIM5a levels. Data shown are from one
representative of three independent experiments.
doi:10.1371/journal.ppat.1000074.g005
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induced degradation of the restriction factor, potentially leading
to artifacts due to general inhibition of protein synthesis. Virus
titration experiments demonstrated markedly greater restriction
in the transduced cells vs. rhesus macaque FRhK-4 cell line,
indicating that the 293T cells overexpress TRIM5arh (our
unpublished observations). Furthermore, while cycloheximide
treatment had only a minor effect on restriction in FRhK-4
cells, the drug markedly reduced restriction in 293T cells (Figure
S4). To probe the physiological relevance of our observations
made in 293T cells, we sought a means of detecting endogenous
TRIM5a protein in rhesus macaque cells. Using a monoclonal
antibody against native TRIM5a for immunoblotting, we
detected a band that was consistent in terms of molecular
weight with TRIM5arh that was also absent in cells lacking
TRIM5arh (data not shown). To confirm that the band is
TRIM5a, we transfected FRhK-4 cells with either a TRIM5arh -
specific siRNA duplex or a non-targeting control siRNA duplex
and quantified the intensity of this band by immunoblotting. As
shown in Figure 7A and B, transfection with TRIM5arh-specific
siRNA resulted in a 72% decrease in intensity of the relevant
band vs. FRhK-4 cells treated with the non-targeting control.
Cells treated with the TRIM5arh-specific also exhibited a tenfold
increase in permissiveness to infection with HIV-1 (data not
shown). HIV-1 infection of FRhK-4 cells was not altered by
treatment with the non-targeting siRNA control. As expected,
treatment with either siRNA duplex did not affect permissiveness
to SIV infection (data not shown). These results indicated that
the monoclonal antibody is capable of detecting endogenous
TRIM5arh in FRhK-4 cells. They further demonstrated that the
transduced 293T cells express a 3.3 fold higher level of TRIM5a
than FRhK-4 cells (Figure 7B).
We next sought to determine if endogenous TRIM5arh was
destabilized by HIV-1 in rhesus macaque cells. FRhK-4 cultures
were inoculated with HIV-1 in the presence or absence of
cycloheximide and the stability of TRIM5arh in response to
infection was analyzed by immunoblotting. Initial experiments
showed no effect of cycloheximide treatment on TRIM5arh
levels in HIV-1-exposed cells (data not shown); therefore the
drug was removed in all subsequent experiments. We observed
that TRIM5arh levels were stable in FRhK-4 cells over the
4 hour period (Figure 7C and D). Infection with HIV-1 resulted
in accelerated decay of endogenous TRIM5arh in rhesus
macaque cells without any requirement of inhibition of protein
synthesis.
We next sought to determine if the loss of TRIM5arh was
specifically due to restriction or was a non-specific effect
resulting from viral infection. In the absence of cycloheximide
we infected FRhK-4 cells with equivalent titers of HIV-1 or
SIVmac239 GFP reporter viruses. As seen in Figure 8A and B,
infection with HIV-1 resulted in a potent loss of TRIM5arh while
infection with SIV resulted in only a slight loss of TRIM5arh as
compared to the control cells. We conclude that infection by HIV-1
results in a rapid loss of TRIM5arh in target cells and that this loss is
directly related to the ability of TRIM5arh to restrict infection by the
incoming virus.
HIV-1-Induced Destabilization of Endogenous TRIM5a
Requires Active Proteasomes
We sought to determine if inhibition of proteasome function
would restore TRIM5arh stability in rhesus macaque cells. FRhK-
4 cells were exposed to HIV-1 in the presence or absence of
MG132 for a period of four hours, and the levels of TRIM5arh
were measured by immunoblotting. As can be seen in Figure 8C
Figure 6. HIV-1-induced destabilization of TRIM5a is blocked
by the proteasome inhibitor MG132. (A and B) 293T cells
expressing HA-tagged TRIM5arh were cultured for 1 hour with
cycloheximide and DMSO (Mock) or MG132 then exposed to HIV-
1(VSV) with DMSO or MG132 (open or filled circles, respectively) or D10
media containing DMSO or MG132 (open or filled diamonds,
respectively). Panel B shows quantitation of TRIM5a levels utilizing
Odyssey imaging software. Data in this figure are from one of two
independent experiments. (C). 293T cells expressing myc-His6-tagged
TRIMCyp were cultured for 1 hour with cycloheximide and DMSO or
MG132. The cells were then exposed for 5 hours to; VSV-G-pseudo-
typed HIV-GFP with either DMSO or MG132, VSV-G-pseudotyped HIV-
GFP with the G89V capsid mutation (G89V) with either DMSO or MG132,
or media alone containing DMSO or MG132 (Mock). (B) Quantitation of
TRIMCyp levels utilizing Odyssey imaging software. Data in this figure
are expressed as the average of the duplicate determinations, with the
error bars depicting the range of values.
doi:10.1371/journal.ppat.1000074.g006
TRIM5a Is Degraded upon Restriction of HIV-1
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Flow cytometry analysis of GFP signal in a small subset of the
infected cells showed no difference in infection levels resulting
from inhibition of proteasome function, which is consistent with
previously published results. These results indicate that HIV-1-
induced destabilization of TRIM5arh in rhesus macaque cells
requires proteasome activity. They further suggest that the results
we observed with TRIM5a-transduced 293T cells are unlikely to
be an artifact of cycloheximide treatment.
Figure 7. HIV-1 specifically induces destabilization of TRIM5a
in rhesus macaque cells. (A) Duplicate cultures of 293T-TRIM5arh and
FRHK-4 cells were transfected on two consecutive days with siRNAs
specific for TRIM5arh (TRIM5a) or a non-targeting control siRNA (NTC).
72 hours after the second transfection, proteins were extracted and
analyzed by immunoblotting with a TRIM5a–specific monoclonal
antibody. (B) Quantitation of TRIM5arh levels in siRNA-transfected cells
by Odyssey imaging software. TRIM5arh levels following siRNA
knockdown are expressed as the average of the duplicate determina-
tions with the error bars depicting the range of values. (C) FRhK-4 cells
were challenged with HIV-GFP(VSV) or media alone (Mock). Zero hour
timepoint represents TRIM5a levels in uninfected cells. (D) Quantitation
of TRIM5arh levels. Results shown are from one representative of three
independent experiments.
doi:10.1371/journal.ppat.1000074.g007
Figure 8. HIV-1-induced turnover of TRIM5a in primate cells
specific to restriction and is blocked by the proteasome
inhibitor MG132. (A) Duplicate cultures of FRhK-4 cells were exposed
to stocks of VSV-G-pseudotyped HIV-GFP (HIV), SIV-GFP (SIV), or media
alone (Mock) for a period of 4 hours then harvested and TRIM5arh levels
quantified by immunoblotting. The zero hour sample corresponds to
uninfected cells. (B) Quantitation of TRIM5arh levels in (A) utilizing
Odyssey imaging software. (C) Duplicate cultures of FRhK-4 cells were
treated for 1 hour with DMSO or MG132, then exposed for 4 hours to:
VSV-G-pseudotyped HIV-GFP with either DMSO or MG132, or media
alone containing DMSO or MG132 (Mock). (D) Quantitation of TRIM5arh
levels utilizing Odyssey imaging software. Data in this figure are
expressed as the averages of the two determinations, with the error
bars spanning the range of values.
doi:10.1371/journal.ppat.1000074.g008
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While it is well established that TRIM5a limits the host range of
many retroviruses, the precise mechanism of restriction remains
undefined. TRIM5a can specifically associate with assemblies of
HIV-1 CA-NC protein in vitro, and genetic evidence indicates that
TRIM5a and TRIMCyp require an intact or semiintact viral
capsid for binding [60,61]. However, the detailed molecular
consequences of the binding interaction to the viral core remain
poorly defined. Two lines of evidence have implicated the
ubiquitin-proteasome system in restriction. First, the d isoform of
TRIM5, which has a RING domain identical to that of TRIM5a,
exhibits E3 activity in vitro [56]. Deletion or mutation of the RING
domain in TRIM5a results in significant loss of restriction efficacy
[44,49]. TRIM5a is ubiquitinated in cells, although a role of this
modification in retrovirus restriction has not been established [55].
Second, inhibition of proteasome activity alters the stage at which
TRIM5a-mediated restriction occurs [58,59]. The latter observa-
tion led us to hypothesize that the proteasome may participate in
restriction by degrading a complex of TRIM5a with one or more
incoming viral proteins. To test this, we asked whether exposure of
cells to HIV-1 alters the stability of TRIM5arh. We observed that
inoculation with HIV-1 results in an accelerated turnover of the
restriction factor. Similar effects were observed in both 293T and
HeLa cells (data not shown), suggesting that TRIM5a destabili-
zation is not specific to a unique cell type. HIV-1 challenge
resulted in destabilization of TRIM5arh but not TRIM5ahu.
Likewise, TRIM5ahu was destabilized by inoculation of cells with
restriction-sensitive N-MLV particles but not by unrestricted B-
MLV. Similar results were seen in cells expressing the HIV-1-
specific restriction factor TRIMCyp. Treatment of target cells with
CsA, which blocks TRIMCyp restriction of HIV-1, or infection
with virus containing mutations that prevent CypA binding
[4,5,38], did not affect TRIMCyp stability. Specific loss of
TRIM5a from cells expressing different primate alleles of the
protein also correlated very well with the ability of those alleles to
restrict HIV or SIV. The HIV-1-induced destabilization of
TRIM5arh and TRIMCyp was prevented by inhibition of cellular
proteasome activity. Destabilization of TRIM5arh by HIV-1 was
also observed in a primate derived cell line without the need of
cycloheximide to inhibit protein synthesis. This destabilization was
specific for the restricted HIV-1 and was not observed in cells
infected with an unrestricted virus. Inhibition of proteasome
function restored TRIM5arh stability in response to infection by
HIV-1 in the rhesus macaque cells. We conclude that TRIM5-
related restriction factors are targeted for degradation by a
proteasome-dependent mechanism following encounter of a
restriction-sensitive retroviral core.
TRIM5a forms heterogenous structures in cells referred to as
cytoplasmic bodies (CBs). While the role of CBs in restriction is
unclear, TRIM5a protein in these structures rapidly exchanges with
soluble TRIM5a, indicating that the protein is highly dynamic
within cells [62]. We observed that most of the cellular TRIM5a can
be degraded in response to exposure to a restriction-sensitive
retrovirus, which implies that a majority of cellular TRIM5a
molecules can engage incoming viral cores. If the CB-associated
TRIM5a is inaccessible to incoming virus, our observation that a
restricted virus can induce degradation of the majority of the
TRIM5a molecules suggests that this protein rapidly redistributes to
a compartment accessible to incoming virus.
TRIM5a and TRIMCyp are subject to proteasome-dependent
turnover under steady-state conditions, yet its rapid turnover is not
a prerequisite for restriction activity [55,63]. Accordingly,
proteasome inhibitors do not overcome restriction ([57]; Figure
S5). Nonetheless, the effect of virus exposure on TRIM5a stability
had heretofore not been reported. While alterations of specific
individual portions of TRIM5a may alter its intrinsic stability, our
results indicate that TRIM5a encounter with a restricted core
results in degradation of the restriction factor by a proteasome-
dependent mechanism.
Retrovirus uncoating is a poorly characterized process, but can be
definedasthedisassemblyoftheviral capsidfollowing penetration of
the viral core into the target cell cytoplasm. Studies of HIV-1 CA
mutants indicate that the stability of the viral capsid is properly
balanced for productive uncoating in target cells: mutants with
unstable capsids are impaired for viral DNA synthesis, suggesting
that premature uncoating is detrimental to reverse transcription
[64]. Thus a plausible mechanism for restriction is that binding of
TRIM5a to the viral capsid inhibits infection directly by physically
triggering premature uncoating in target cells [65,66]. In this model,
TRIM5a, perhaps with one or more cofactors, promotes the
physical decapsidation of the virus core independently of proteolysis.
Consistent with this view are studies demonstrating that TRIM5a
restriction is associated with decreased recovery of sedimentable CA
protein in lysates of acutely-infected cells [65,66]. However, these
studies fell short of demonstrating that the sedimentable CA protein
was associated with intact viral cores. Furthermore, a recent study
reported that treatmentofcellswithproteasomeinhibitorsprevented
TRIM5a-dependent loss of particulate CA protein [67], indicating
the potential involvement of proteasome activity in TRIM5a-
induced virus uncoating.
Other studies further implicate the activity of the proteasome in
TRIM5a-dependent restriction. Inhibition of proteasome activity
rescues HIV-1 reverse transcription in TRIM5a-expressing cells,
revealing a downstream block to nuclear import mediated by the
restriction factor [58,59]. Engagement of the viral capsid by
TRIM5a may lead to proteasomal degradation of a TRIM5a-CA
complex, resulting in functional decapsidation of the viral core and
a premature uncoating phenotype. Consistent with this model,
TRIM5a restriction has been associated with decreased intracel-
lular accumulation of HIV-1 CA [68]. In addition, a recent study
of MLV particle-mediated RNA cellular transfer reported reduced
accumulation of viral CA protein in cells in a manner that was
correlated with restriction by TRIM5a, and this effect was
reversed by proteasome inhibition [69]. Unfortunately, our own
efforts to detect an effect of TRIM5a on the stability of the
incoming HIV-1 CA have thus far yielded negative results; thus we
are reluctant to conclude at this stage that a specific component of
the viral core is degraded as a complex with TRIM5a. Another
potential mechanism is that proteasomal engagement of TRIM5a
bound to the virus core results in physical dissociation of CA from
the core followed by its release from TRIM5a, thus leading to
destruction of the restriction factor and decapsidation of the core
but not necessarily degradation of CA [70]. Genetic evidence from
abrogation-of-restriction studies indicates that TRIM5a binding
requires an intact or semiintact viral capsid [60], suggesting that
TRIM5a binding to CA is highly dependent on avidity resulting
from multivalent interactions with the polymeric viral capsid. It is
thus plausible that CA is released from TRIM5a following forced
uncoating. This model is attractive in its ability to reconcile most,
if not all, of the reported data regarding the mechanism of
restriction by TRIM5a.
HIV-1 infection in many primate cell lines exhibits biphasic
titration curves, and restriction can be abrogated in trans by high
concentrations of VLPs, indicating that virus restriction is
saturable. While it is generally assumed that the saturation occurs
via sequestration of the restriction factor by the incoming virus,
our results reveal another potential mechanism. Degradation of
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bilityto infection byincoming virus,suggesting that loss of restriction
athighvirusinputmayoccur viadegradationof therestrictionfactor
itself. Consistent with this view, treatment with MG132 resulted in a
three-fold decrease in HIV-1 infection of FRhK-4 as well as OMK
cells, while infection by unrestricted SIV was inhibited only
marginally (Figure S5). This result, coupled with our observations
of proteasome-dependent degradation of TRIM5a proteins in
restrictive cells, suggests that depletion of TRIM5a via the
proteasome contributes to the saturability of restriction.
The potential involvement of ubiquitylation in virus-induced
degradation of TRIM5a degradation warrants further study. The
autoubiquitylation of TRIM5d observed in vitro suggests that
TRIM5a may be ubiquitylated in trans upon polymerization of the
restriction factor on a retroviral capsid. However, we have been
unable to detect accumulation of cellular ubiquitylated TRIM5a
species following HIV-1 inoculation either in the presenceor absence
of proteasome inhibitors (ourunpublished observations).While many
cellular proteins are regulated by ubiquitin-dependent proteolysis,
ubiquitin-independent proteasomal degradation is also well docu-
mented (reviewed in [71]). Most E3 ligases are not degraded
following ubiquitylation of a substrate, yet notable exceptions exist.
The E3 enzyme Mdm2 is degraded following its ubiquitylation of its
target, p53 [72], and the stability of several E3 ligases is related to
their ubiquitylation status resulting from autoubiquitylation [73–75].
It will therefore be of interest to determine whether HIV-1-induced
degradation of TRIM5a is dependent on host cell ubiquitylation and
the TRIM5a RING domain.
The early post-entry stage of infection remains a fundamentally
obscure part of the retrovirus life cycle. Our results provide novel
evidence for a role for proteasome activity in TRIM5a restriction.
Further mechanistic studies of TRIM5a may reveal novel
approaches to antiviral therapy and fundamental insights into
the molecular details of HIV-1 uncoating.
Materials and Methods
Plasmids
pLPCX-TRIM5arh (rhesus macaque), pLPCX-TRIM5ahu
(human), pLPCX-TRIM5asp (spider monkey), and pLPCX-
TRIM5atam (tamarin monkey) were generous gifts from Dr. J.
Sodroski [3,31]. pCIG-N and pCIG-B were generous gifts from J.
Stoye [76]. pNL4-3 was obtained from the NIH AIDS Research
and Reference Reagent Program and the env gene inactivated as
previously described [77]. pHIV-GFP [78], pSIV-GFP [23], and
pCL-ampho [79] were gifts from D. Gabuzda, P. Bieniasz, and B.
Naviaux, respectively. R9-G89V was made by PCR mutagenesis
of the wild type HIV-1 provirus R9 utilizing site-specific primers
and verified by sequencing. pHIV-G89V-GFP was made by
transfer of the BssHII-EcoRI fragment of R9-G89V into the
BssHII-EcoRI sites of pHIV-GFP and verified by restriction
digest. pHCMV-G was provided by J. Burns [80]. pBABE-eGFP
was created by transfer of the BamHI-EcoRI fragment from
peGFP (Clontech) into the BamHI-EcoRI sites of pBABE-puro
[81]. pBABE-rhTRIM5a and pBABE-huTRIM5a were generat-
ed by PCR amplification of the rhesus and human TRIM5a
sequences from pLPCX-TRIM5arh and pLPCX-TRIM5ahu
using primers TRIM5a-1(S)-Eco 59- GATCGAATTCAGCTAC-
TATGGCTTCTGGAATCCTG-39 and pTM1-TRIMHA-R 59-
GTCTCGAGTCAAGCGTAGTCTGGGACG-39 (EcoRI and
XhoI sites underlined). The PCR products were digested and
ligated into the EcoRI and SalI sites in pBABE-puro. A TRIMCyp
cDNA was generated from oligo dT-primed owl monkey kidney
cell cDNA and PCR amplified using the TRIM5a-1(S)-Eco and
primer 59-CTAGCTCGAGTACAGAAGGAATGATCTGG-39
(XhoI site underlined) specific to the 39-UTR of the human
cyclophilin A gene. This amplification results in a Arg to Gly
substitution at codon 4 as compared to the original TRIMCyp
cDNA. The product was ligated into the EcoRI-XhoI sites of
plasmid CMX-PL1. The Myc-His6 tag was added to TRIMCyp
by PCR amplification of CMX-PL1-TRIMCyp with TRIM5a-
1(S)-Eco and primer 59-GTCTCGAGAGAGCTTGGTGAGCA-
CAGAGTCATGG-39 (XhoI site underlined). This product was
then digested with EcoRI and XhoI and ligated into pcDNA 3.1/
myc-His A (Invitrogen). The TRIMCyp containing the myc-(His)6
epitope tag was then amplified from TRIMCyp-pcDNA3.1/myc-
His A using TRIM5a-1(S)-Eco and the primer pcDNA3.1 HIS-Sal
59-ACGTCGACTTTCAATGGTGATGGTGATGATGACC-
39, and the product digested with EcoRI and SalI and ligated into
the corresponding sites in pBABE-puro. All constructs were
verified via bidirectional DNA sequencing.
Chemicals
MG132 and cycloheximide were purchased from Sigma-
Aldrich and used at final concentrations of 25 mM and 50 mM,
respectively. Cyclosporin A was purchased from CalBiochem used
at 2.5 mM final concentration. Epoxomicin was purchased from
Boston Biochem and used at 10 mM. The cathepsin inhibitor E64
was purchased from Sigma-Aldrich and was used at 40 mM.
Cells and Viruses
FRhK-4 cells were purchased from the American Type Culture
Collection. Cells were cultured in Dulbecco’s modified Eagle’s
medium containing 10% fetal bovine serum and 1% penicillin/
streptomycin. VSV-G-pseudotyped HIV-1NL4.3,H I V - G F P ,a n d
SIV-GFP viruses were produced by calcium phosphate transfection
of 293T cells with proviral plasmid DNA (23 mg) and pHCMV-G
(7 mg). N- and B-tropic MLV virus stocks were prepared by co-
transfection of 23 mg pCIG-N or pCIG-B plasmids with pHCMV-G
(7 mg)ontothecellline293TeGFP.Thiscelllineisaclonegenerated
from 293T cells previously transduced with the retroviral vector
pBABE-eGFP and isolated by limiting dilution and selected for high
levels of GFP expression. Transfected cells were washed after
24 hours and replenished with fresh media. Supernatants were
harvested 48–72 hours after transfection, clarified by passing
through 0.45 mm filters, and stored in aliquots at 280uC. Retrovirus
stocks for transductionof TRIM5a alleleswereharvested from 293T
cells transfected with the plasmids pCL-ampho (10 mg), the
appropriate TRIM5a vector (15 mg), and pHCMV-G (5 mg).
Viruses were collected 48 hours after transfection and used to
transduce 293T cells. All 293T cell lines expressing TRIM5a
proteins were polyclonal cell populations obtained by selection of
transduced cells with puromycin. TRIMCyp-expressing cells were
obtained by isolation of a single cell clone via limiting dilution. HIV-
1 was strongly restricted in these cells, and restriction was prevented
by the addition of 5 mg/ml cyclosporin A (CsA).
Infection Protocol
Cells were seeded in 6-well plates at a density of 1 to 1.25610
6
cells/well and incubated overnight. Prior to infection, cultures
were treated for 1 hour in 50 mM cycloheximide to block protein
synthesis. In experiments involving proteasome inhibitors, cells
were incubated with both cycloheximide and the appropriate
inhibitor for 1 hour prior to infection. Viral stocks containing
cycloheximide, polybrene (5 mg/mL), CsA (2.5 mM), and protea-
some inhibitors were prewarmed to 37uC prior to addition to cells.
After culturing for 1 hr, media from zero hour timepoints was
removed and 1 ml of PBS was added. Cells were then detached
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the pellets frozen at 280uC. Cells that were challenged with virus
had media removed and replaced with viral stock and were
returned to 37uC. Individual cultures were harvested hourly using
same procedure as previously described for the zero hour
timepoints. All cell pellets were frozen at 280uC prior to analysis.
For experiments utilizing FRhK-4 cells the cells were seeded in 6
well plates at a density of 3610
5 cells/well and incubated
overnight. Prewarmed viral stocks containing polybrene (5 mg/
mL) were added the following day with a well harvested at the
time of viral addition serving as the zero hour timepoint. Cells
were incubated with the viral stock for the indicated time period
then trypsinized, placed in fresh D10 media at a 1:1 volume,
pelleted, washed in 1 mL complete D10 media to inactivate
trypsin, repelleted, washed 2 times in 1 mL PBS, then frozen at
280uC. In experiments with FRhK-4 cells involving MG132, the
cells were incubated with inhibitor for one hour prior to viral
addition with the zero hour timepoint being an uninfected well
harvested after 1 hour pretreatment.
siRNA Knockdown of TRIM5arh
293T and FRhK-4 cells were seeded at a density of 2610
5 cells
per well in 6-well plates and incubated overnight. 24 hours later,
TRIM5arh-specific siRNA [3], or a non-targeting control siRNA
(Dharmacon), were diluted to a concentration of 3 mMi n1 6siRNA
buffer then transfected into cells using Dharmafect 1 transfection
reagent and OptiMEM I (Gibco) according to manufacturers
protocol (Dharmacon). Cells were then incubated overnight and
retransfected with siRNAs again the following day utilizing the
identical protocol. 48 hours after the first siRNA transfection the
cells were removed from the 6-well plates and plated onto a 10 cm
dish in complete D10 media at a ratio of 1 well to 1 10 cm dish and
incubated for either 24 or 48 hours. 24 hours later, one 10 cm dish
of either TRIM5arh-specific siRNA treated cells or non-targeting
control treated cells were trypsinized and replated in24 well plates at
a density of 2610
5 cells/well then incubated overnight. The
following day the remaining two 10 cm dishes of siRNA treated
cells weretrypsinized,diluted 1:1inD10 media,pelleted,washed 16
in D10 media to inactivate trypsin, repelleted, washed 26in 1 mL
PBS per wash, repelleted, then frozen at 280uC. Cells that had been
seeded the prior day in the 24 well plates were then infected with
dilutions of HIV and SIV-GFP, incubated for 48 hours, then
analyzed for GFP expression by flow cytometry.
Protein Analyses
Cell pellets were thawed and lysed in a solution containing
100 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 0.5% NP-40.
Nuclei were pelleted via centrifugation at 16,0006g for 10 minutes
and post-nuclear supernatants were removed. Protein levels were
quantified via BCA assay (Pierce). Samples, normalized for total
protein, were denatured in SDS and subjected to electrophoresis
on 4–20% acrylamide gradient gels (BioRad). Proteins were
transferred to nitrocellulose and probed with HA-epitope tag-
specific rat monoclonal antibody (3F10, Roche) and Alexa Fluor
680 conjugated goat anti-rat IgG (Molecular Probes). Cells
expressing TRIMCyp were probed with the myc epitope-specific
mouse monoclonal antibody (9E10, Invitrogen) and Alexa Fluor
680-conjugated goat anti-mouse IgG (Molecular Probes). Proteins
extracted from FRhK-4 cells were probed the TRIM5a-specific
mouse polyclonal antibody (IMG-5354, Imgenex) and Alexa Fluor
680 conjugated goat anti-mouse IgG (Molecular Probes). All
immunoblots were probed with b-actin-specific rabbit monoclonal
antibody (A2228, Sigma) and IRDye800-conjugated goat anti-
rabbit IgG (Rockland). Dilutions of antibodies were 1:1000 and
1:5000 for primary and secondary respectively with the exception
of IMG-5354 which was used at a dilution of 1:2000. Bands were
detected by scanning blots with the LI-COR Odyssey Imaging
System using both 700 and 800 channels, and integrated
intensities were determined using the LI-COR Odyssey band
quantitation software with the median top-bottom background
subtraction method. The TRIM5a band intensities were then
normalized to the signals from the corresponding b-actin bands.
All signals were then expressed as a percentage of the initial
TRIM5a/actin band intensity ratio.
Genes used in this study
TRIM5arh (AY523632); TRIM5ahu (AF220025); TRIMCyp
(AY646198); TRIM5atam (AY740615); TRIM5asp (AY740616).
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